Schreiber V, Kitzmueller M, Poxhofer M, Gintersdorfer S, Neudorfer C, Lichtneckert M, Dittrich C, Czejka M. Impact of co-administered drugs on drug monitoring of capecitabine in patients with advanced colorectal cancer.
Anticancer Res 2014;
34:3371-3376. [PMID:
24982342]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
BACKGROUND
Drug monitoring is a useful tool for obtaining detailed information about the disposition of a drug in an individual patient during chemotherapy. According to the international guidelines, the analytical assay for quantification of a compound in biological samples must be validated. Among a number of parameters, peak purity is an important requirement.
MATERIALS AND METHODS
We analyzed pharmacokinetics in patients who received chemotherapy with capecitabine and up to 10 various co-medications.
RESULTS
Out of seven investigated co-administered drugs, we found evidence that the proton pump inhibitor pantoprazole causes peak interferences with capecitabine during high-performance liquid chromatography analysis. Therefore quantification of capecitabine in plasma samples can be inaccurate.
CONCLUSION
We recommend an altered time schedule for co-administered drugs or changing the mobile phase used in the assay.
Collapse